Answers are grounded in this paper and cite their sources.
Cunninghamella bertholletiae is an opportunistic fungal organism of the order Mucorales that is found in soil and is a rare cause of human disease.1 The few reported cases of C. bertholletiae have predominantly involved immunocompromised hosts and have been associated with very poor outcomes.2-6 To date, therapeutic options have included surgical debridement and high-dose amphotericin B deoxycholate, which have shown very limited efficacy. We report a case of C. bertholletiae endocarditis in an immunosuppressed patient. The patient was treated with amphotericin B followed by amphotericin B plus posaconazole, an investigational medication with in vitro activity against some agents of mucormycosis.7-11 To our knowledge, this is the third case of C. bertholletiae endocarditis reported in the literature and the second reported use of posaconazole for the treatment of mucormycosis. CASE PRESENTATION A 32-year-old male landscape architect with a history of pure red cell aplasia was admitted to the hospital with a 2-week history of progressive shortness of breath and chest pain. Four years previously, he was treated for Staphylococcus aureus aortic valve endocarditis that developed in the setting of a permanent indwelling catheter. He had a history of multiple blood transfusions. He had been receiving long-term immunosuppressive therapy with prednisone and cyclosporine and received antithymocyte globulin 6 weeks prior to this admission. Five weeks prior to admission, he developed malaise and fatigue. Three weeks prior to admission, because of complaints of left-sided chest pain, dyspnea on exertion, a nonproductive cough, and night sweats, empiric oral ciprofloxacin and fluconazole were prescribed. A magnetic resonance imaging of the chest obtained 2 weeks prior to admission revealed a small left pleural effusion. On physical examination, the patient was a well-nourished Caucasian male who appeared fatigued, but was in no acute distress. The blood pressure was 110/50 mm Hg; pulse, 102 beats per minute; temperature, 101.4°F; respiratory rate, 20 breaths per minute; and oxygen saturation, 98% on room air. Pulmonary examination revealed decreased breath sounds and dullness to percussion at the lower left base. A grade II/VI diastolic murmur was heard at the left lower sternal border. Abdominal and neurologic examinations were unremarkable. There was no peripheral edema. A blackish discoloration 2 cm in diameter was present at the lateral tip of the right index finger. No Janeway lesions, Osler nodes, or splinter hemorrhages were present. Initial laboratory data were significant for a white blood cell count of 4700/mm3, hemoglobin of 8.7 g/dL, platelets of 83,000/mm3, erythrocyte sedimentation rate of 151 mm/h, creatinine of 1.8 mg/dL, creatine kinase of 794 U/L, and troponin I greater than 50 ng/mL. A chest radiograph showed mild cardiomegaly and a left pleural effusion. Blood cultures were drawn, and intravenous vancomycin and ceftriaxone were given. An electrocardiogram revealed sinus tachycardia with prominent ST elevations in the inferolateral leads. The patient underwent urgent cardiac catheterization that revealed normal coronary arteries. A transthoracic echocardiogram demonstrated moderate aortic regurgitation with aortic valve thickening, inferoapical hypokinesis, and an ejection fraction of 40%. A transesophageal echocardiogram performed on hospital day 2 revealed severe aortic regurgitation and confluent valvular vegetations that extended approximately 3 cm superior to the aortic root. Liposomal amphotericin B was added at a dose of 3 mg/kg/day. On hospital day 3, the patient developed rapidly progressive aortic insufficiency and was intubated for hypoxic respiratory failure. He then underwent emergent aortic valve replacement and debridement of the ascending aorta. Histologic examination of the aortic valve revealed evidence of extensive invasion of broad hyphae with short irregular branching (Fig. 1). Blood cultures did not yield growth; however, on hospital day 7, tissue cultures of the aortic valve grew C. bertholletiae. The dose of liposomal amphotericin B was increased to 5 mg/kg/day. On hospital day 8, a new embolic lesion was noted on the patient's right thumbnail. Over the course of the next several days, the patient developed ventricular tachycardia and complete heart block requiring pacemaker placement. Many new embolic lesions were noted on the trunk and all 4 extremities. On hospital day 15, a repeat transesophageal echocardiogram showed a normal prosthetic aortic valve with circumferential vegetations in the aortic root extending into the orifices and proximal portions of the left and right coronary arteries. The dose of liposomal amphotericin B was increased to 10 mg/kg/day. On hospital day 18, oral posaconazole therapy was initiated on a compassionate-use basis at a dose of 400 mg/day. Over the next few days, the patient's peripheral embolic lesions appeared to have decreased in size, although he remained febrile and became progressively lethargic. On hospital day 22, a computed tomographic scan of the head showed several lesions consistent with septic emboli, and a chest computed tomographic scan showed a new infiltrate within the right middle lobe. A repeat transesophageal echocardiogram revealed severe mitral regurgitation and perforation of the anterior leaflet of the mitral valve, as well as progressive involvement of the ascending aorta, prosthetic aortic valve, and pulmonic valves. On the 24th day of hospitalization, he became acutely hypoxic and hypotensive and expired. No autopsy was performed at the request of the family.FIGURE 1: Hyphae of C. bertholletiae seen in aortic valve section.DISCUSSION C. bertholletiae is a rare cause of human disease, although it may be the third most common agent of mucormycosis after Rhizopus and Absidia species.1,12 This report is the 36th case of Cunninghamella infection in the English language literature,2-6 and the third case of endocarditis.6,13 As with other opportunistic mold infections, most cases of Cunninghamella infection occur in hosts with significant immune compromise. Our patient had a history of pure red cell aplasia requiring chronic immunosuppression. Hematologic malignancies or dyscrasias have been reported in 64% of Cunninghamella cases.2 Other common underlying conditions include solid organ transplantation (11%) and diabetes mellitus (8%).2 The majority of cases (86%) have occurred in males, raising the possibility of occupational exposure to the organism, as may have occurred for our patient, a landscape architect. Cunninghamella infection most frequently presents with pulmonary involvement (78%). There have been only 2 other reports of Cunninghamella endocarditis, with this case and another one presenting with an acute coronary syndrome.3 This is consistent with previous reports of major epicardial artery thrombosis reported for 3 (18%) of 17 cases of cardiac involvement due to other zygomycetes.14 Cunninghamella infections are associated with a very high mortality-only 6 of 36 patients (17%) reported in the literature have survived. For patients with visceral involvement (ie, excluding cases limited to skin, superficial wounds, or sinuses), the reported mortality is 94%. The high reported mortality of Cunninghamella infections emphasizes the need for early aggressive surgical debridement when the diagnosis is established antemortem. Results thus far with medical therapies have been disappointing, and there are several reports of Cunninghamella isolates with high minimum inhibitory concentrations against amphotericin B.2 High doses of amphotericin B products have repeatedly failed to cure these infections, and new antifungal therapeutics are needed to address the problems of these and other invasive mucormycoses. Posaconazole, an investigational triazole antifungal agent, is reported have in vitro activity against zygomycetes.7-11 In one comparison of posaconazole versus other triazoles and amphotericin B, the mean MICs against 37 clinical isolates of zygomycetes, including 5 isolates of Cunninghamella, were lowest for posaconazole.8 A separate study demonstrated that the MICs of 83 clinical fungal isolates were lower for posaconazole than 2 echinocandins-this difference was especially marked against Rhizopus, the only zygomycete tested.10 The first case report of cure of mucormycosis with posaconazole has recently been published.15 Our patient received posaconazole and showed some evidence of improvement in his cutaneous embolic lesions before experiencing further embolic phenomena and valvular insufficiency. However, the extent of his disease and our inability to perform further surgical debridement make it overwhelmingly likely that any antifungal regimen would have failed.
No takes yet. Share an insight, caveat, or question.
Barton et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: